AU2005307151B2 - Gaba-steroid antagonists and their use for the treatment of CNS disorders - Google Patents

Gaba-steroid antagonists and their use for the treatment of CNS disorders Download PDF

Info

Publication number
AU2005307151B2
AU2005307151B2 AU2005307151A AU2005307151A AU2005307151B2 AU 2005307151 B2 AU2005307151 B2 AU 2005307151B2 AU 2005307151 A AU2005307151 A AU 2005307151A AU 2005307151 A AU2005307151 A AU 2005307151A AU 2005307151 B2 AU2005307151 B2 AU 2005307151B2
Authority
AU
Australia
Prior art keywords
gaba
pregnan
3beta
5alpha
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005307151A
Other languages
English (en)
Other versions
AU2005307151A1 (en
Inventor
Torbjorn Backstrom
Per Lundgren
Ming-De Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Umecrine AB
Original Assignee
Umecrine AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine AB filed Critical Umecrine AB
Publication of AU2005307151A1 publication Critical patent/AU2005307151A1/en
Application granted granted Critical
Publication of AU2005307151B2 publication Critical patent/AU2005307151B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2005307151A 2004-11-18 2005-11-07 Gaba-steroid antagonists and their use for the treatment of CNS disorders Ceased AU2005307151B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62951104P 2004-11-18 2004-11-18
US60/629,511 2004-11-18
PCT/SE2005/001671 WO2006054938A1 (en) 2004-11-18 2005-11-07 Gaba-steroid antagonists and their use for the treatment of cns disorders

Publications (2)

Publication Number Publication Date
AU2005307151A1 AU2005307151A1 (en) 2006-05-26
AU2005307151B2 true AU2005307151B2 (en) 2011-10-20

Family

ID=36407411

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005307151A Ceased AU2005307151B2 (en) 2004-11-18 2005-11-07 Gaba-steroid antagonists and their use for the treatment of CNS disorders

Country Status (11)

Country Link
US (2) US8114860B2 (OSRAM)
EP (1) EP1812009B1 (OSRAM)
JP (1) JP4914368B2 (OSRAM)
CN (1) CN101076340B (OSRAM)
AU (1) AU2005307151B2 (OSRAM)
BR (1) BRPI0518359A2 (OSRAM)
CA (1) CA2585359C (OSRAM)
DK (1) DK1812009T3 (OSRAM)
ES (1) ES2423493T3 (OSRAM)
MX (1) MX2007006032A (OSRAM)
WO (1) WO2006054938A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4914368B2 (ja) * 2004-11-18 2012-04-11 ウメクライン アーベー Ｇａｂａ−ステロイド拮抗剤およびｃｎｓ疾患の治療のためのその使用
PL2711371T3 (pl) * 2006-11-21 2018-06-29 Asarina Pharma Ab Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
US20110086828A1 (en) * 2009-10-07 2011-04-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Treatment of alcohol abuse and alcoholism using modulators of neurosteroid binding sites on gabaa receptors
WO2011087441A1 (en) 2010-01-14 2011-07-21 Umecrine Mood Ab A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068068A2 (fr) * 2000-03-17 2001-09-20 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Composes se liant au cytosquelette
WO2003059357A1 (en) * 2001-12-27 2003-07-24 Umecrine Ab Pregnane steroids for use in the treatment of cns disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4614499A (en) * 1985-04-29 1986-09-30 Universite Laval Simulator for use as a neurosurgical aid in determining potential paths for the implantation of probes through the human body
ATE307592T1 (de) * 1998-03-11 2005-11-15 Torbjoern Backstroem Epiallopregnanolon zur behandlung von krankheiten des cns
US20030125311A1 (en) * 2000-03-17 2003-07-03 Etienne-Emile Baulieu Compounds capable of binding with the cytoskeleton
JP4914368B2 (ja) 2004-11-18 2012-04-11 ウメクライン アーベー Ｇａｂａ−ステロイド拮抗剤およびｃｎｓ疾患の治療のためのその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068068A2 (fr) * 2000-03-17 2001-09-20 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Composes se liant au cytosquelette
WO2003059357A1 (en) * 2001-12-27 2003-07-24 Umecrine Ab Pregnane steroids for use in the treatment of cns disorders

Also Published As

Publication number Publication date
DK1812009T3 (da) 2013-08-05
US20120142657A1 (en) 2012-06-07
ES2423493T3 (es) 2013-09-20
CN101076340B (zh) 2011-01-12
US20080070876A1 (en) 2008-03-20
EP1812009B1 (en) 2013-05-15
US8114860B2 (en) 2012-02-14
JP2008525317A (ja) 2008-07-17
EP1812009A1 (en) 2007-08-01
US8372824B2 (en) 2013-02-12
JP4914368B2 (ja) 2012-04-11
CN101076340A (zh) 2007-11-21
CA2585359A1 (en) 2006-05-26
BRPI0518359A2 (pt) 2008-11-18
WO2006054938A1 (en) 2006-05-26
MX2007006032A (es) 2007-10-17
EP1812009A4 (en) 2010-08-11
CA2585359C (en) 2013-01-08
AU2005307151A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
US8119619B2 (en) Pregnane steroids and their use in the treatment of CNS disorders
CN1270718C (zh) 表别孕烷醇酮在制备治疗甾族化合物诱导的疾病的药物中的应用
WO2009142594A1 (en) The use of 3beta-ethenyl, methyl, 3alpha-hydroxy-steroids for the treatment of cns disorders
US8372824B2 (en) GABA-steroid antagonists and their use for the treatment of CNS disorders
Claman Glucocorticosteroids II: the clinical responses
RU2413516C2 (ru) Гамк-стероидные антагонисты и их применение в лечении нарушений цнс
US11026953B2 (en) 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 18 JUL 2007.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired